Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionGlobeNewsWire • Tuesday
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/24
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia DrugInvestors Business Daily • 04/15/24
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/07/24
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial OfficerGlobeNewsWire • 01/22/24
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical StudyGlobeNewsWire • 11/27/23
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/01/23
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentGlobeNewsWire • 10/10/23
Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developerProactive Investors • 09/27/23
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsMarket Watch • 09/27/23